A Phase 1b/2 trial of CPI-444 in RCC patients that have failed anti-PD-(L)1 and a tyrosine kinase inhibitor

Trial Profile

A Phase 1b/2 trial of CPI-444 in RCC patients that have failed anti-PD-(L)1 and a tyrosine kinase inhibitor

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Jun 2018

At a glance

  • Drugs CPI 444 (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Jun 2018 According to a Corvus Pharmaceuticals media release,Status changed from planning to recruiting.
    • 08 Mar 2018 New trial record
    • 01 Mar 2018 According to a Corvus Pharmaceuticals media release, the company is planning to amend a Phase 1/1b trial of CPI-444 in combination with Tecentriq (see profile 262434) to enroll patients in a trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top